JO3818B1 - مركبات حمض أيزوكسازول هيدروكساميك على هيئة مثبطات LpxC - Google Patents

مركبات حمض أيزوكسازول هيدروكساميك على هيئة مثبطات LpxC

Info

Publication number
JO3818B1
JO3818B1 JOP/2015/0318A JOP20150318A JO3818B1 JO 3818 B1 JO3818 B1 JO 3818B1 JO P20150318 A JOP20150318 A JO P20150318A JO 3818 B1 JO3818 B1 JO 3818B1
Authority
JO
Jordan
Prior art keywords
compounds
acid compounds
hydroxamic acid
lpxc inhibitors
isoxazole
Prior art date
Application number
JOP/2015/0318A
Other languages
English (en)
Inventor
Karur Subramanian
Kevin Sweeney Zachary
Fu Jiping
Lapointe Guillaume
Marie Madera Ann
Jin Xianming
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3818B1 publication Critical patent/JO3818B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بصفة عامة بمركبات بالصيغة <strong><span dir="LTR"> I</span></strong> كما تم وصفها في هذه الوثيقة والتركيبات التي تحتوي على تلك المركبات، بالإضافة إلى طرق استخدام تلك المركبات لعلاج الإصابات البكتيرية <strong><span dir="LTR">.</span></strong> في سمات معينة ، يقدم الاختراع طرق وتركيبات تتضمن تلك المركبات لعلاج الإصابات الناتجة عن البكتريا سالبة الجرام<strong><span dir="LTR">.</span></strong>
JOP/2015/0318A 2014-12-16 2015-12-16 مركبات حمض أيزوكسازول هيدروكساميك على هيئة مثبطات LpxC JO3818B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462092402P 2014-12-16 2014-12-16

Publications (1)

Publication Number Publication Date
JO3818B1 true JO3818B1 (ar) 2021-01-31

Family

ID=55025302

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0318A JO3818B1 (ar) 2014-12-16 2015-12-16 مركبات حمض أيزوكسازول هيدروكساميك على هيئة مثبطات LpxC

Country Status (41)

Country Link
US (3) US9549916B2 (ar)
EP (1) EP3233843B1 (ar)
JP (1) JP6697466B2 (ar)
KR (1) KR20170094214A (ar)
CN (1) CN107001295B (ar)
AR (1) AR107428A1 (ar)
AU (1) AU2015365455B2 (ar)
BR (1) BR112017011422A2 (ar)
CA (1) CA2969803A1 (ar)
CL (1) CL2017001460A1 (ar)
CO (1) CO2017005870A2 (ar)
CR (1) CR20170260A (ar)
CU (1) CU24443B1 (ar)
CY (1) CY1122305T1 (ar)
DK (1) DK3233843T3 (ar)
EA (1) EA032138B1 (ar)
EC (1) ECSP17045737A (ar)
ES (1) ES2756300T3 (ar)
GT (1) GT201700132A (ar)
HR (1) HRP20192009T1 (ar)
HU (1) HUE047225T2 (ar)
IL (1) IL252373B (ar)
JO (1) JO3818B1 (ar)
LT (1) LT3233843T (ar)
MA (1) MA41185B1 (ar)
ME (1) ME03546B (ar)
MX (1) MX2017007980A (ar)
MY (1) MY195743A (ar)
PE (1) PE20171044A1 (ar)
PH (1) PH12017501019B1 (ar)
PL (1) PL3233843T3 (ar)
PT (1) PT3233843T (ar)
RS (1) RS59507B1 (ar)
SG (1) SG11201704053WA (ar)
SI (1) SI3233843T1 (ar)
SV (1) SV2017005462A (ar)
TN (1) TN2017000207A1 (ar)
TW (1) TWI693215B (ar)
UA (1) UA121225C2 (ar)
UY (1) UY36448A (ar)
WO (1) WO2016097995A1 (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719401B (zh) 2013-05-17 2021-02-21 美商英塞特公司 作為jak抑制劑之聯吡唑衍生物
US10071973B2 (en) * 2016-06-14 2018-09-11 Novartis Ag Crystalline isoxazole hydroxamic acid compounds
CN107434766A (zh) * 2017-08-09 2017-12-05 凯莱英医药集团（天津）股份有限公司 烷烃羟胺类化合物的合成装置及连续合成方法
IL276725B2 (en) 2018-02-16 2024-09-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
WO2020105660A1 (ja) * 2018-11-21 2020-05-28 大正製薬株式会社 新規イミダゾール誘導体
US11685731B2 (en) 2020-06-02 2023-06-27 Incyte Corporation Processes of preparing a JAK1 inhibitor
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN112603936B (zh) * 2020-12-28 2022-08-02 仲恺农业工程学院 一种抑制气单胞菌属的组合物及其制备方法与应用
WO2022173758A1 (en) * 2021-02-11 2022-08-18 Forge Therapeutics, Inc. Antibacterial compounds
CN117279898A (zh) * 2021-02-11 2023-12-22 布莱克史密斯医药公司 抗菌化合物
EP4408853A1 (en) * 2021-09-28 2024-08-07 Blacksmith Medicines, Inc. Lpxc inhibitors and uses thereof
WO2024067813A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和其医药上的用途
WO2024067812A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
EP0418667B1 (de) 1989-09-22 1995-08-16 BASF Aktiengesellschaft Carbonsäureamide
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
EP1025228A4 (en) 1997-10-21 2002-09-18 Human Genome Sciences Inc HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
JP2002502607A (ja) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
EP1196186B1 (en) 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
KR101145252B1 (ko) 2003-01-08 2012-05-24 유니버시티 오브 워싱톤 항균제
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
BRPI0410785A (pt) 2003-05-23 2006-06-20 Wyeth Corp molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN102203258A (zh) 2008-07-02 2011-09-28 新兴产品开发西雅图有限公司 TGF-β拮抗剂多靶点结合蛋白
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
SI2350129T1 (sl) 2008-08-25 2015-11-30 Amplimmune, Inc. Sestavki PD-1 antagonistov in postopek njihove uporabe
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
CA2735929C (en) * 2008-09-19 2013-12-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
EP2488489A2 (en) * 2009-10-13 2012-08-22 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
EP2512474B1 (en) * 2009-12-16 2014-11-05 Pfizer Inc N-linked hydroxamic acid derivatives useful as antibacterial agents
ME02505B (me) 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimerni vezujući proteini i njihove upotrebe
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
KR20140023869A (ko) 2010-11-10 2014-02-27 아카오젠, 인코포레이티드 하이드록삼산 유도체 및 세균 감염 치료에서의 이들의 사용
ES2626457T3 (es) 2011-03-07 2017-07-25 Pfizer Inc. Derivados de fluoro-piridinona útiles como agentes antibacterianos
KR20130140868A (ko) * 2011-04-08 2013-12-24 화이자 인코포레이티드 항세균제로서 유용한 이속사졸 유도체
SG193458A1 (en) 2011-04-08 2013-10-30 Pfizer Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
SI2785375T1 (sl) 2011-11-28 2020-11-30 Merck Patent Gmbh Protitelesa proti PD-L1 in uporabe le-teh
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections

Also Published As

Publication number Publication date
US10029994B2 (en) 2018-07-24
LT3233843T (lt) 2019-12-10
WO2016097995A1 (en) 2016-06-23
UY36448A (es) 2016-07-29
JP2018500333A (ja) 2018-01-11
PT3233843T (pt) 2019-11-26
HUE047225T2 (hu) 2020-04-28
PE20171044A1 (es) 2017-07-19
KR20170094214A (ko) 2017-08-17
AU2015365455B2 (en) 2019-01-17
CO2017005870A2 (es) 2017-10-20
TN2017000207A1 (en) 2018-10-19
MY195743A (en) 2023-02-08
US20160166548A1 (en) 2016-06-16
SI3233843T1 (sl) 2019-12-31
CR20170260A (es) 2017-08-21
CN107001295B (zh) 2021-02-02
EA032138B1 (ru) 2019-04-30
MA41185B1 (fr) 2019-12-31
CU20170084A7 (es) 2017-11-07
EP3233843B1 (en) 2019-10-16
TW201629024A (zh) 2016-08-16
IL252373A0 (en) 2017-07-31
US20170088525A1 (en) 2017-03-30
MX2017007980A (es) 2017-09-29
PH12017501019A1 (en) 2017-12-04
JP6697466B2 (ja) 2020-05-20
ME03546B (me) 2020-07-20
GT201700132A (es) 2019-10-10
CL2017001460A1 (es) 2017-12-22
AR107428A1 (es) 2018-05-02
UA121225C2 (uk) 2020-04-27
HRP20192009T1 (hr) 2020-02-07
AU2015365455A1 (en) 2017-06-08
IL252373B (en) 2019-11-28
ES2756300T3 (es) 2020-04-27
EA201791353A1 (ru) 2017-10-31
ECSP17045737A (es) 2019-02-28
CY1122305T1 (el) 2021-01-27
US9549916B2 (en) 2017-01-24
US20180030004A1 (en) 2018-02-01
CN107001295A (zh) 2017-08-01
DK3233843T3 (da) 2019-11-18
SV2017005462A (es) 2018-04-04
EP3233843A1 (en) 2017-10-25
PL3233843T3 (pl) 2020-04-30
RS59507B1 (sr) 2019-12-31
SG11201704053WA (en) 2017-06-29
US9815804B2 (en) 2017-11-14
CU24443B1 (es) 2019-10-04
BR112017011422A2 (pt) 2018-04-03
PH12017501019B1 (en) 2017-12-04
CA2969803A1 (en) 2016-06-23
TWI693215B (zh) 2020-05-11

Similar Documents

Publication Publication Date Title
PH12017501019A1 (en) Isoxazole hydromaxamic acid compounds as lpxc inhibitors
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
EA201491970A1 (ru) Циклические мостиковые простые эфиры в качестве ингибиторов dgat1
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2017012073A (es) Compuestos de minociclina para biodefensas.
ZA202002093B (en) Antibacterial compounds
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
MX2017012759A (es) Moléculas pequeñas que contienen boro como agentes antiprotozoarios.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EA202090750A1 (ru) Производные глюконовой кислоты для применения в лечении и/или предупреждении инфекций, вызываемых микроорганизмами
MX2019009362A (es) Compuestos heterociclicos novedosos y sus usos en la prevencion o el tratamiento de infecciones bacterianas.
PH12015502060A1 (en) Hydrochloride salts of an antibiotic compound
JO3477B1 (ar) مركبات أحادي باكتام عضوية لعلاج العدوى البكتيرية
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.